BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• Press Releases

  Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

  November 13, 2024

   · 

  6 min read
• Press Releases

  Cerus Corporation to Participate in Upcoming Investor Conferences

  November 13, 2024

   · 

  1 min read
• Press Releases

  Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

  November 13, 2024

   · 

  13 min read
• Press Releases

  Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery

  November 13, 2024

   · 

  4 min read
• Press Releases

  INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer’s Disease

  November 13, 2024

   · 

  4 min read
• Press Releases

  Circadia C200 System Gets FDA 510(k) Clearance, Transforming Senior Care With Contactless Heart Rate, Respiratory Rate, Motion, and Bed Exit Monitoring

  November 13, 2024

   · 

  3 min read
• Press Releases

  Ethics Board Approval Granted for Lexaria’s 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

  November 13, 2024

   · 

  7 min read
• Press Releases

  Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

  November 13, 2024

   · 

  4 min read
• Press Releases

  Longhorn Vaccines and Diagnostics Composite Peptide Vaccine Combats Sepsis Related to Antimicrobial Resistant Tuberculosis

  November 13, 2024

   · 

  3 min read
• Press Releases

  Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in Multiple Myeloma

  November 13, 2024

   · 

  3 min read